| Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up M Ekstedt, H Hagström, P Nasr, M Fredrikson, P Stål, S Kechagias, ... Hepatology 61 (5), 1547-1554, 2015 | 2194 | 2015 |
| Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up C Söderberg, P Stål, J Askling, H Glaumann, G Lindberg, J Marmur, ... Hepatology 51 (2), 595-602, 2010 | 948 | 2010 |
| Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD H Hagström, P Nasr, M Ekstedt, U Hammar, P Stål, R Hultcrantz, ... Journal of hepatology 67 (6), 1265-1273, 2017 | 918 | 2017 |
| Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives M Elmberg, R Hultcrantz, A Ekbom, L Brandt, S Olsson, R Olsson, ... Gastroenterology 125 (6), 1733-1741, 2003 | 339 | 2003 |
| A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C–associated liver cirrhosis S Aleman, N Rahbin, O Weiland, L Davidsdottir, M Hedenstierna, N Rose, ... Clinical Infectious Diseases 57 (2), 230-236, 2013 | 286 | 2013 |
| Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long‐term follow‐up study H Hagström, P Nasr, M Ekstedt, U Hammar, P Stål, R Hultcrantz, ... Hepatology communications 2 (1), 48-57, 2018 | 255 | 2018 |
| Liver fibrosis in non-alcoholic fatty liver disease-diagnostic challenge with prognostic significance P Stål World Journal of Gastroenterology: WJG 21 (39), 11077, 2015 | 190 | 2015 |
| Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet–a randomised controlled trial M Holmer, C Lindqvist, S Petersson, J Moshtaghi-Svensson, V Tillander, ... JHEP Reports 3 (3), 100256, 2021 | 127 | 2021 |
| Overweight in late adolescence predicts development of severe liver disease later in life: a 39 years follow-up study H Hagström, P Stål, R Hultcrantz, T Hemmingsson, A Andreasson Journal of hepatology 65 (2), 363-368, 2016 | 91 | 2016 |
| Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls P Holmström, J Marmur, G Eggertsen, M Gåfvels, P Stål Gut 51 (5), 723-730, 2002 | 90 | 2002 |
| Cardiovascular risk factors in non‐alcoholic fatty liver disease H Hagström, P Nasr, M Ekstedt, U Hammar, P Stål, J Askling, R Hultcrantz, ... Liver International 39 (1), 197-204, 2019 | 89 | 2019 |
| Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics S Wahlin, Y Floderus, P Stål, P Harper Journal of internal medicine 269 (3), 278-288, 2011 | 85 | 2011 |
| Accuracy of noninvasive scoring systems in assessing risk of death and liver-related endpoints in patients with nonalcoholic fatty liver disease H Hagström, P Nasr, M Ekstedt, P Stål, R Hultcrantz, S Kechagias Clinical gastroenterology and hepatology 17 (6), 1148-1156. e4, 2019 | 82 | 2019 |
| Elevated serum ferritin is associated with increased mortality in non‐alcoholic fatty liver disease after 16 years of follow‐up H Hagström, P Nasr, M Bottai, M Ekstedt, S Kechagias, R Hultcrantz, ... Liver International 36 (11), 1688-1695, 2016 | 81 | 2016 |
| Iron increases ethanol toxicity in rat liver P Stål, R Hultcrantz Journal of hepatology 17 (1), 108-115, 1993 | 80 | 1993 |
| Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease H Hagström, P Nasr, M Ekstedt, S Kechagias, K Önnerhag, E Nilsson, ... Scandinavian journal of gastroenterology 52 (2), 159-165, 2017 | 79 | 2017 |
| Liver transplantation for erythropoietic protoporphyria in Europe S Wahlin, P Stal, R Adam, V Karam, R Porte, D Seehofer, BK Gunson, ... Liver Transplantation 17 (9), 1021-1026, 2011 | 73 | 2011 |
| Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis B Bengtsson, P Stål, S Wahlin, NK Björkström, H Hagström Liver International 39 (6), 1098-1108, 2019 | 72 | 2019 |
| Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? P Edenvik, L Davidsdottir, A Oksanen, B Isaksson, R Hultcrantz, P Stål Liver International 35 (7), 1862-1871, 2015 | 72 | 2015 |
| Biliary dysplasia, cell proliferation and nuclear DNA‐fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma A Bergquist, H Glaumann, P Stål, GS Wang, U Broome Journal of internal medicine 249 (1), 69-75, 2001 | 68 | 2001 |
